Dogwood Therapeutics (DWTX) Research & Development (2020 - 2026)

Dogwood Therapeutics has reported Research & Development for 7 years, with the latest figure at $3.2 million in Q2 2026.

• On a quarterly basis, Research & Development rose 26.33% year-over-year to $3.2 million in Q2 2026; TTM through Jun 2026 was $22.8 million, a 189.84% increase from a year earlier, with the FY2025 full-year figure at $21.9 million, up 519.28% from the prior year.
• Research & Development was $3.2 million for Q2 2026 at Dogwood Therapeutics, up from $2.7 million in the prior quarter.
• The five-year high for Research & Development was $14.5 million in Q3 2025, with the low at $298321.0 in Q4 2023.
• Average Research & Development over 5 years is $2.3 million, with a median of $2.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Research & Development sank 82.03% in 2023, then jumped 2613.45% in 2025.
• Over 5 years, Research & Development stood at $1.3 million in 2022, then slumped by 76.54% to $298321.0 in 2023, then jumped by 676.33% to $2.3 million in 2024, then gained by 0.94% to $2.3 million in 2025, then surged by 38.87% to $3.2 million in 2026.
• The last three Research & Development figures came in at $3.2 million (Q2 2026), $2.7 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.